Patients and treatment protocols
This cohort included 111 newly diagnosed ALL pediatric patients with
CDKN2A deletion.All patients were diagnosed and treated according to
CCLG-ALL 2015 protocol[1] at Blood Disease
Hospital of CAMS & PUMC between September 2016 and December 2019.The
following patients were not included in this cohort:a .patients
who diagnosed as mature B-lineage ALL or
mixed-phenotype acute leukemia
(MPAL)(excluding ALL with myeloid antigen
expression);b .patients developed from chronic myeloid leukemia
blast crisis(CML-BP),another cancer or immunodeficiency
disease;c .patients who had undergone chemotherapy or radiation
in three months(excluding emergency radiotherapy to relieve the
oppression symptoms);d .patients who used to treat
glucocorticoid no less than7 days between one week to one month before
enrollment.The immunophenotype was distinguished by a panel of
monoclonal antibodies including markers for B-lineage
cells(CD10,CD19,TdT,cyμ,sIgM,CD20,cyCD22,CD22,cyCD79a),T-lineage
cells(CD1a,CD2,CD3,CD4,CD5,CD7,CD8,TCRαβ,TCRγδ,cyCD3)or myeloid
cells(CD11b,CD13,CD14,CD15,CD33,CD41,CD61,CD64,CD65,CD71,GPA,cyMPO).
The protocols described in this study were approved by the Ethics
Committee,Institute of Hematology & Blood Disease Hospital,CAMS &
PUMC.All patients or their legal guardians signed written informed
consent before treatment.